Welcome to our dedicated page for METLIFE SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on METLIFE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into METLIFE's regulatory disclosures and financial reporting.
MetLife Inc. director William E. Kennard reported an additional grant-related acquisition of common stock. On June 9, 2026, he acquired 322 shares of MetLife common stock at $85.57 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, he holds 46,823 common shares directly. The filing also notes 10 common shares held indirectly in the MetLife Policyholder Trust established for eligible policyholders.
MetLife Inc. director Laura J. Hay reported an acquisition of 39 shares of MetLife common stock on a Form 4. The shares were credited at a reference price of $85.57 per share through imputed dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors, rather than an open-market purchase. Following this routine compensation-related award, Hay directly holds 5,731 MetLife common shares.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 61 shares of MetLife common stock through an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a reference price of $85.57 per share.
Following this award-related transaction, Johnson directly holds 8,911 shares of MetLife common stock. The filing reflects a routine, compensation-linked increase in his equity position rather than an open-market purchase.
MetLife Inc. director Carla A. Harris reported a small stock-based compensation increase. On the reported date, she acquired 42 shares of MetLife common stock at $85.57 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this award, she directly holds 10,528 common shares.
MetLife Inc. director Christian Stephane Mumenthaler reported an acquisition of 20 shares of MetLife common stock on a grant/award basis at $85.57 per share. The footnote explains this was an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, he directly holds 2,865 shares of MetLife common stock.
MetLife director Daniel S. Glaser reported a small share award. On June 9, 2026, he acquired 7 shares of MetLife common stock at $85.57 per share through a grant tied to the MetLife Deferred Compensation Plan for Non-Management Directors. After this award, he holds 2,108 shares directly and 198 shares indirectly in a GRAT.
MetLife Inc. director Robert Glenn Hubbard acquired 678 shares of Common Stock as a compensation-related award. The shares were credited on June 9, 2026 at $85.57 per share as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
After this transaction, Hubbard directly holds 106,557 MetLife common shares. The filing characterizes the event as a grant or award, not an open-market purchase.
MetLife Inc. reported that President, U.S. Business Ramy Tadros acquired 127 shares of common stock on June 9, 2026. The shares were credited at an imputed price of $85.57 per share through reinvested dividends in the MetLife Leadership Deferred Compensation Plan, increasing his direct holdings to 216,946 shares. This reflects routine compensation-related accrual rather than an open-market purchase.
MetLife EVP & Chief Risk Officer Marlene Debel reported option exercises and share sales in common stock. On June 1, 2026, she exercised employee stock options to acquire 10,712 shares at $45.50 and 10,600 shares at $46.85 per share. The same day, she completed an open‑market sale of 21,312 shares at a weighted average price of $81.5889, with individual trade prices between $81.57 and $81.65. Following these transactions, she directly owns 154,380 shares of MetLife common stock.
MET submitted a Rule 144 notice reporting proposed sales of Common stock on 06/01/2026. The excerpt lists securities to be sold tied to options granted 02/28/2017 (10,600 shares) and 03/02/2018 (10,712 shares), each shown with a cash settlement method.